Apr 3 |
Matinas BioPharma prices $10 million registered direct offering
|
Apr 3 |
Matinas BioPharma Prices $10 Million Registered Direct Offering
|
Apr 1 |
Matinas BioPharma Holdings, Inc. (AMEX:MTNB) Q4 2023 Earnings Call Transcript
|
Mar 29 |
Matinas BioPharma Holdings, Inc. (MTNB) Q4 2023 Earnings Call Transcript
|
Mar 28 |
Q4 2023 Matinas BioPharma Holdings Inc Earnings Call
|
Mar 27 |
Matinas Biopharma GAAP EPS of -$0.11, revenue of $1.1M
|
Mar 27 |
Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update
|
Mar 25 |
Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation
|
Mar 22 |
Why Is Fungal Infections-Focused Matinas BioPharma Stock Trading Higher On Friday?
|
Mar 22 |
Three Patients with Invasive Fusarium Infection in Matinas BioPharma’s Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical Response
|